secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001104659-22-115424
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma Q3 2022: YUPELRI sales up 35% YoY; $1.1B TRELEGY deal closed; debt-free
--------------------------------------------------------------------------------

- Implied 35% share of YUPELRI net sales $18.7M, up 35% YoY; Viatris collaboration revenue $12.4M.
- Closed TRELEGY royalty sale to Royalty Pharma for ~$1.1B upfront; gain of $1.14B; now debt-free with $486.8M cash.
- Initiated $250M capital return; purchased GSK's 9.6M shares at $9.75/shr; Dutch tender up to $95M extended to Nov 17.
- Operating expenses guidance: R&D $45-55M, SG&A $35-45M for FY2022 (excl. share-based comp and one-time costs).
- Ampreloxetine Phase 3 study (CYPRESS) in MSA patients with nOH to start Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465922115424/0001104659-22-115424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465922115424/tm2229828d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-115424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer